instruction:
In this task, you are given a passage which has a question and the context. You have to generate an answer to the question based on the information present in the context.
question:
Context: Pemphigus vulgaris (PV) is an autoimmune blistering disease mediated by IgG autoantibodies targeting desmogleins (Dsgs). The anti-CD20 monoclonal antibody rituximab is increasingly used in corticosteroid-resistant PV patients. In a subset of rituximab-treated patients in remission, high ELISA index values have been reported; however, their significance remains so far unclear.', 'To address the discrepancy between anti-Dsg3 serum antibody titers and disease severity.', '6 rituximab-treated PV patients were prospectively followed-up for two years and anti-Dsg3 autoantibodies levels and pathogenic activity were measured.', 'All patients achieved complete remission without any serious side effects. Both anti-Dsg3 autoantibodies (p = 0.031) and their pathogenic activity (p = 0.003) were significantly related to disease severity. However, in selected patients, the dissociation index was a more sensitive indicator for PV clinical activity than the ELISA index.\Question: Does the pathogenic activity of anti-desmoglein autoantibodies parallel disease severity in rituximab-treated patients with pemphigus vulgaris?
answer:
Our findings have demonstrated the existence of non-pathogenic autoantibodies in PV patients in remission, establishing the basis for the design of a system able to precisely monitor the course of disease.

question:
Context: The majority of cancer chemotherapy can lead to bone marrow depression, which often affects clinical response as chemotherapy can not be carried out with enough dosage on time. The platelets decrease is one of the problems caused by bone marrow depression. Though the clinical response of hyodermic "IL-11" is affirmed to advance platelets presently, it is limited by expensive price. Other agents that can be taken orally with suitable price and equal authenticity are less reported. The author observed clinical response of platelets decrease adopting traditional Chinese medicine "Sheng Ban Recipe"(SBR).', 'Totally 103 patients with platelets decrease after chemotherapy from July 1994 to Jannary 2002. They were randomly divided into two groups: SBR plus common treatment group and common treatment alone group. The previous group take 1 package SBR for twice drink per day. Common treatment group give common therapy only. The follow-up period is 2 weeks.', 'Among the 55 cases in SBR group, noticeable efficiency 20%, efficiency 50.9%, total efficiency 70.9%, which is evidently superior to common group.\Question: Do [ Observation of clinical response of '' sheng ban recipe '' for platelets decrease after chemotherapy ]?
answer:
"Sheng Ban Recipe" can effectively treat thrombocytopenia after chemotherapy, which helps to reduce the necessary of intravenous drip of platelets and the risk of hemorrhage.

question:
Context: To determine if bilateral S3 lead placement during the stage I trial period improves the "success" rate for advancing to stage II (permanent) sacral neuromodulator placement.', 'A retrospective chart review of 124 (20 male and 104 female) patients undergoing stage I sacral neuromodulation (InterStim, Medtronic, Minneapolis, Minnesota) implantation for the treatment of refractory voiding dysfunction was performed. Patients were divided into two cohorts based on unilateral versus bilateral stage I lead placement in the S3 foramina. Both groups were then evaluated and compared with regards to overall "success", defined as progression from stage I to stage II placement.', 'Fifty-five (44%) patients underwent unilateral stage I lead placement and 69 (56%) received bilateral S3 leads. Successful stage I trials were reported in 32/55 (58%) and 53/69 (76%) of unilateral and bilateral cohorts, respectively (P = 0.03). Five wound infections were reported-2 (3.6%) following unilateral and 3 (4.3%) after bilateral stage I lead placement. No other complications were encountered.\Question: Do unilateral versus bilateral stage I neuromodulator lead placement for the treatment of refractory voiding dysfunction?
answer:
Bilateral stage I neuromodulation trial provides a significantly higher rate of improvement in refractory voiding symptoms to allow for the progress to stage II implantation.